Alumis

Alumis reports topline results from the ONWARD3 extension study: 54% of patients with moderate-to-severe plaque psoriasis reached PASI‑100 after 48 weeks of envudeucitinib treatment, and 75% achieved PASI‑90. The analysis was based on 773 patients in the treatment arms; an integrated evaluation of the 890 originally randomized patients showed 66% PASI‑90 and 47% PASI‑100 after 48 weeks. The treatment continued to show a consistent safety profile with no new safety signals. Alumis plans to submit a marketing application to the FDA in Q4 2026 and expects topline data from the Phase 2b LUMUS study in SLE in Q3 2026. » More on de.investing.com

Alumis shares hit an all-time high of $30.67, lifting market capitalization to about $3.73 billion; the stock is only 0.96% below its 52-week high and has risen more than 843% since its 52-week low. InvestingPro currently rates the stock as strongly overvalued, despite a year-to-date gain of 745.71%. Positive Phase III data for Envudeucitinib and an accelerated approval filing targeted for Q4 2026 are driving analyst updates; Guggenheim, Stifel, Cantor Fitzgerald and H.C. Wainwright raised or reiterated positive ratings and price targets. » More on de.investing.com